Publication
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Journal Paper/Review - Jan 12, 2023
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Units
PubMed
Doi
Contact
Citation
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
Type
Journal Paper/Review (English)
Journal
Leukemia 2023; 37
Publication Date
Jan 12, 2023
Issn Electronic
1476-5551
Pages
699-701